Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06877702 · ClinicalTrials.gov registry record · Phase 1
A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT06877702 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 85 participants.
The verdict
NCT06877702, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, drug levels, and relative bioavailability of alternate formulations of BMS-986460 in healthy adult male participants.
Interventions
- DRUG BMS-986460
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2025-03-19 |
| Est. Completion | 2025-12-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06877702
The ClinicalTrials.gov registry entry for NCT06877702 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-986460 is the first listed.
NCT06877702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06877702 about?
NCT06877702 is a clinical study titled "A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants". The purpose of this study is to assess the safety, tolerability, drug levels, and relative bioavailability of alternate formulations of BMS-986460 in healthy adult male participants.
What is the current status of trial NCT06877702?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2025-03-19. Estimated completion is 2025-12-17.
What interventions are being tested in trial NCT06877702?
The interventions under investigation include: BMS-986460 (DRUG).
Who is sponsoring clinical trial NCT06877702?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.